Cambrian Bioworks is a Bio-tech startup that raised $1.45 million in its ongoing seed funding round led by the Inrani Family office. The funding round saw the participation of various new and existing investors including the CEO Vaibhav Hegde. The startup plans to use these fresh proceeds to fuel its business growth, scale its operations, enhance its research & development, and expand in the market. This marks the first round of investment for the company since its inception.
The co-founder of Cambrian Bioworks, Vaibhav Hegde told inc42 in an interview that molecular diagnostics is crucial for precise diagnosis, disease subtyping, and the therapy selection in cancer care treatment. This investment will enable the company to strengthen its technology and make its tools more precise for diagnosis. The startup is mainly focused on developing innovative products and expanding its operations. The Biotech startup provides molecular-focused technologies to tackle the ethical challenges in cell culture. The firm aims to revolutionize healthcare and cell-related biotechnologies globally and offer the best solutions.
The startup develops an automated molecular diagnostic platform. The company provides innovative products to find applications in Genomics, oncology, AMR detection, and rare disease testing. The startup also launched a Cambrian nucleic acid extraction platform Mantra. This platform provides high-quality DNA or RNA for PCR testing and genomics in hospitals and labs. Cambrian Bioworks claims to offer advanced biotech solutions to address the challenges in the diagnostic analysis process while improving efficiency. The startup aims to provide affordable and advanced solutions to improve biotechnology. The company uses cutting-edge technologies to transform the biotechnology industry across India.
Cambrian Bioworks plans to use some of its investment to expand biotech research and advance PCR-related technologies. The startup faces competition from other biotech companies including Boutique Venture Partners, FemHealth Ventures, and Jifan Biotechnology. The development came just after the biotechnology startup saw increased interest from investors globally. The market research showed that the cell culture market is expected to grow and reach 33 billion USD in the next six years. The co-founder of the company followed the founders of BYJU, OYO, Yubi, and Blusmart as examples of investing in their startup. The investment shows the trust of investors in the startup’s business model and market potential.
Conclusion:
Bengaluru-based biotech startup, Cambrian Bioworks secured $1.45 million in its seed funding round. The funding round saw the participation of the family office of Irani and other investors including the CEO of Cambrian, Vaibhav Hegde. The company intends to use this fresh capital to scale its operations, enhance its platforms, and expand its services in India. The startup is working on creating innovative solutions to address the challenges in the biotechnology market. The company also offers flagship products to find applications in oncology, AMR detection, Genomics, and rare disease testing. This molecular diagnosis plays an important role in precise diagnosis and therapy for cancer care. The startup faces competition from other biotechnology startups in the same market segment.
